SB-Metlina 2.5 mg+850 mg (Tablet)
Unit Price: ৳ 14.00 (30's pack: ৳ 420.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Linagliptin metformin hydrochloride |
| Company | Sunman birdem pharma ltd |
| Also available as |
Title and Categories
- SB-Metlina Combination Oral hypoglycemic preparations
Dimensions
Color Options
Functions
- Improves glycemic control in adults with type 2 diabetes mellitus
- Inhibits DPP-4 enzyme
- Stimulates insulin release in a glucose-dependent manner
- Decreases glucagon secretion
- Lowers both basal and postprandial plasma glucose
- Improves insulin sensitivity
- Decreases hepatic glucose production
- Decreases intestinal absorption of glucose
- Increases peripheral glucose uptake and utilization
Materials
Technical Specifications
- Dosage of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily
- Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride
- Dosage individualized based on effectiveness and tolerability
- Maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg
- Dosage escalation should be gradual to reduce gastrointestinal side effects
- Dosage individualized based on effectiveness and tolerability for extended-release tablet
Design Elements
Usability Features
- Indicated as an adjunct to diet and exercise
Indications
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Pharmacology
- Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4)
- Linagliptin increases the concentrations of active incretin hormones
- Linagliptin stimulates the release of insulin from pancreatic beta cells in a glucose-dependent manner
- Linagliptin decreases the secretion of glucagon from pancreatic alpha cells
- Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug
- Metformin Hydrochloride mechanism of action is different from sulfonylureas
Dosage & Administration
- Dosage should be individualized based on effectiveness and tolerability
- Recommended starting dose based on previous treatment with Metformin Hydrochloride or Linagliptin
Interaction
- Potential interaction with cationic drugs eliminated by renal tubular secretion
- Potential interaction with carbonic anhydrase inhibitors
- Potentially reduced efficacy when administered with a strong P-gp or CYP 3A4 inducer
- Certain drugs may affect glycemic control and lead to loss of control
Contraindications
- Contraindicated in patients with renal impairment
- Contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis)
- Contraindicated in hypersensitivity to Linagliptin or Metformin Hydrochloride
Side Effects
- Common side effects include nasopharyngitis and diarrhea
- Hypoglycemia is more common when combined with sulfonylureas
Pregnancy & Lactation
- Use during pregnancy only if clearly needed
- Caution should be exercised when administered to a lactating mother
Precautions & Warnings
- Discontinue immediately and institute supportive therapy in case of lactic acidosis
- Promptly discontinue in case of suspected pancreatitis
- Temporarily discontinue during radiologic studies with contrast materials or surgical procedures
- Hematologic parameters should be monitored annually for Vitamin B12 levels
- Careful instructions on alcohol consumption, other medicines, counseling, travel, and emergencies
- May cause hypoglycemia and should be treated promptly
Overdose Effects
- Usual supportive measures for overdose
- Linagliptin is unlikely to be removed by dialysis
- Metformin Hydrochloride is dialyzable
- No dose-related clinical adverse drug reactions reported with Linagliptin overdose
- Hypoglycemia and lactic acidosis reported with Metformin Hydrochloride overdose
Therapeutic Class
- Combination Oral hypoglycemic preparations
Storage Conditions
- Keep in a cool & dry place (below 30°C)
- Protected from light & moisture
- Keep out of the reach of children